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We propose that deregulation of proliferation, together with a reduction in apoptosis, creates a platform that is both necessary
and can be sufficient for cancer. The secondary traits of diverse neoplasms are a consequence of cell proliferation, tissue
expansion, and other outcomes of this platform.
Introduction:The cause of cancer
An absurd proposal
Much of the general public sees cancer as a modern day plague
that culls our nearest and dearest with the capriciousness of the
ancient Black Death. Others see its continuing onslaught, in the
face of the vast resources directed at its conquest, as the
irrefutable evidence of humanity’s hubris. However, to the can-
cer patient, cancer is a terrifying alien entity invading his body
and treatable only with medicines of medieval harshness and
dubious efficacy. For the oncologist, cancer is a legion of recon-
dite diseases whose diversity complicates therapy to the point
where its efficacy can only be expressed by statistics, while to
many basic scientists, cancer is a collection of well-established
cell lines that conveniently take up foreign DNA and proliferate
endlessly. In reality, a mutually agreeable definition of cancer is
not possible. For the sake of this review, we will choose to use
perhaps the most generally applicable definition of cancer as
the pathological expansion of a tissue resulting in morbidity.
The possible causes and mechanisms of cancer have pro-
voked much debate and controversy. However, out of this tumult
has emerged one widely accepted principle that both the
process of carcinogenesis and the tumors in which it results are
extremely complex. This conclusion is reinforced by the mani-
festation of cancer as a bewilderingly diverse panoply of dis-
eases, arising in different organs at different times in different
individuals, following unpredictable patterns of progression, and
confounding a rational therapy. Surely, treatment of such a
diversity of diseases requires painstaking assembly of an equiv-
alent diversity of therapies? Perhaps not.
After all, phenotypic diversity in biology need not necessari-
ly imply corresponding causal complexity. For example, iteration
of a common mechanism of cell proliferation has wildly different
consequences depending upon cell type, location, and the con-
tingent responses of neighboring tissues. By analogy, all tumors
could be driven by a common platform of cell expansion yet
nonetheless manifest themselves as diverse and fickle patholo-
gies. In this review, we push this idea to its logical conclusion
and propose the outrageous hypothesis that cancer is not com-
plex at all, but a deceptively simple phenomenon (Figure 1).Our
absurd proposal is this: once conditions are met that provide a
platform for ineluctable cell expansion, much of the characteris-
tic pathology of cancer arises spontaneously as a consequence
of interactions between the expanding mass and its somatic
milieu.
Of course, we would never wish to imply that cell expansion
is the totality of tumorigenesis, since any autonomously
expanding cell population will encounter shifting selective pres-
sures that further shape and dictate its evolutionary trajectory.
However, by stripping away incidental complexities, it is our
hope to distill out the common engine of cancer and so identify
common and tractable therapeutic targets. Specifically, we pro-
pose that rather than arising through the protracted, serial ero-
sion of independent growth restraints, cancers arise from the
rare simultaneous acquisition of the two cooperating conditions
that permit cell expansion—deregulated cell proliferation and
suppressed apoptosis. This, like cancer itself, happens so very
rarely because the two processes are obligatorily interdepen-
dent—deregulated proliferation on its own triggers expeditious
cell death, whereas suppression of apoptosis confers no selec-
tive advantage in the absence of cell proliferation—and so have
to arise together in the same cell at the same time.This cooper-
ative hypothesis for the emergence of cancer is not only in
keeping with the well-characterized synergy exhibited by onco-
genes, but also has the great benefit of solving a great conun-
drum of vertebrate biology: how does the organism achieve
facile cell division where needed yet so effectively suppress the
emergence of unregulated neoplastic clones? According to our
proposal, cells propagate only when in receipt of interlocking
signals that simultaneously promote proliferation and suppress
the consequent apoptosis (Evan and Littlewood, 1998). This is
easily accomplished in the correct somatic context through the
connivance of appropriate neighboring cells, whereas simulta-
neous mutational activation of all requisite cooperating path-
ways in an individual is an event of comforting rarity.
We will prosecute our case by examining three implications
of our hypothesis. First, we will explore why it is normally so dif-
ficult to achieve a combined state of proliferation and sup-
pressed cell death by showing that conditions that promote cell
proliferation necessarily engage the cell death process.We will
then explore how such cell death occurs, so as to understand
how it can become suppressed in cancer. Finally, we will con-
sider how these conditions provide an obligate cancer platform
that defines targets against which we can target appropriate
therapies.
How cancer cells proliferate
Pulling out the stops
Underpinning the relentless and pathological expansion of can-
cers are lesions that compromise control of the proliferation,
survival, differentiation, and migration of tumor cells. Early on in
metazoan evolution, somatic cell autonomy became obligatorily
restricted, and cell fate subsumed to the needs of the whole
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organism.Cancer is the erosion of this metazoan dowry through
the accumulation of genetic damage in somatic cells. In their
landmark review “The Hallmarks of Cancer,” Hanahan and
Weinberg (2000) delineated the principle mechanisms restrain-
ing somatic cell proliferative autonomy that must be abrogated
for cancers to arise. Normal somatic cell proliferation is shack-
led both by an absolute need for external mitogens and sensi-
tivity to inhibition by multiple growth-suppressive signals.
Consequently, deregulation of cell proliferation requires acquisi-
tion of both autonomy from exogenous mitogens and refractori-
ness to normal growth inhibitory signals. Even then, the capaci-
ty to proliferate endlessly is restricted by telomere erosion that
must be independently overcome for cancers to emerge. In
addition, macroscopic tumor growth requires the capacity to
recruit and subvert necessary trophic and vascular support
from neighboring tissues, while an acquired ability to spread
and metastasize marks the most intractable feature of cancer
as a disease. The image is of many independent mechanisms
limiting somatic cell autonomy that can be eroded only by the
protracted and stochastic accretion of multiple mutations, an
accretion reflected in the evident genetic complexity within indi-
vidual cancer cells. In this view, a series of challenges faces the
emerging tumor, and they are met one by one. By having
enough of these hurdles in place, most lifetimes run out before
cancer becomes an issue.We suggest that this need not always
be the way it works. The Hallmarks are undoubtedly real, but
cancer may be rare for another reason.
Antagonistic pleiotropyA decidedly two-faced view of
the world
More recently, it has become clear that the “altruism” of verte-
brate cells is enforced by some remarkably sophisticated evolu-
tionary footwork (Figure 1).The first intimation of this came from
the unexpected discovery that oncoproteins like Myc and E1A
can act as potent inducers of apoptosis.This led to the proposal
that apoptosis might act as an inbuilt failsafe to staunch “inap-
propriate” proliferation of somatic cells (Harrington et al.,
1994b). Many, perhaps all, mechanisms that drive cell prolifera-
tion have the potential to trigger, or sensitize a cell to, apoptosis
(Evan and Littlewood, 1998). Established examples include acti-
vation of the Ras/Raf pathway, deregulated expression of c-Jun,
and almost anything leading to promiscuous activity of the E2F
G1 progression transcription factors. Moreover, other versions
of such antagonistic pleiotropy exist, such as the innate capaci-
ties of activated Raf and Ras oncoproteins to trigger permanent
growth arrest (Lloyd et al., 1997; Serrano et al., 1997) or the
growth inhibitory action of the apoptosis suppressor Bcl-2
(Huang et al., 1997; Linette et al., 1996). A major component of
the differential that couples the oppositely spinning wheels of
proliferation and growth suppression is the ARF/Mdm-2/p53
tumor suppressor pathway (Sherr, 2001); Ras, E1A, Myc, and
E2F all induce ARF, an alternate product of the INK4a locus
which then binds and inactivates Mdm-2, a key part of the ubiq-
uitin ligase that keeps p53 at bay (Lowe, 1999). However, evi-
dence is also emerging for ARF/p53-independent pathways,
underscoring the importance of redundancy in this vitally impor-
tant tumor suppressive mechanism.
Such hardwiring of growth-suppressive mechanisms into
growth-promoting ones is, of course, a very effective way of
staunching malignant progression. Unfortunately, since onco-
proteins are also part of the normal proliferative machinery, this
has the unwanted side effect of inhibiting normal cell growth.
Clearly, there must be some way of distinguishing between nor-
mal and abnormal proliferation. One possibility is that cells are
able specifically to sense “hyperproliferative” signals and
respond by activating the failsafe response. However, in the
case of Myc at least, prevailing evidence suggests that the cel-
lular decision whether to live or die is determined by the avail-
ability of social survival signals which, if present, specifically
gate the apoptotic program and so foster net cell proliferation.
Consequently, Myc is unable to drive cell expansion without the
assistance of cooperating signals; in essence, oncogene coop-
eration by another name. In addition, by both p53-dependent
and -independent mechanisms, Myc sensitizes cells to a
diverse range of pro-apoptotic insults, including nutrient depri-
vation, hypoxia, DNA damage, and death receptor signaling
(Alarcon et al., 1996; Evan et al., 1992; Juin et al., 1999), all like-
ly consequences of tumorigenic growth. In this way, Myc, and by
inference other oncoproteins, establishes “sentinel” functions
that remain dormant in normal cells proliferating in their stress-
free orthotopic environments. However, should a cell encounter
Figure 1. An absurd proposal
Signals that promote proliferation promote apoptosis (this is not an
either/or situation; both occur simultaneously). The apoptosis pathways
so engaged are shown schematically. If apoptosis is blocked by survival
signals, expansion occurs, and the manifestation of this expansion is what
we see as cancer. This proposal stands in sharp contrast to models in which
sequential blocks to transformation are bypassed by mutation and selec-
tion to ultimately produce an autonomous cancer.
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stress or wander into a somatic compartment with inadequate
trophic support, then some of these spring into activity to
ensure the arrest or timely demise of the cell.The importance of
such “sentinel” functions in tumor suppression has long been
intimated by the dramatic oncogenic cooperation observed
between Myc and anti-apoptotic lesions such as overexpres-
sion of Bcl-2 or loss of ARF or p53. With the recent advent of
switchable transgenic Myc models, it has become possible to
directly observe Myc-induced apoptosis in vivo. Indeed, so
potent is the innate tumor suppressive action of Myc-induced
apoptosis that its acute activation in vivo in pancreatic β cells
triggers their immediate and wholesale ablation (Pelengaris et
al., 1999). Such ablation is dramatically transformed into abrupt
tumor progression upon suppression of β cell apoptosis by
expression of Bcl-xL.
Importantly, there is nothing inherent in the mechanisms
underlying proliferation or cell death that requires them to be
connected in this way—rather, antagonistic pleiotropy appears
to have arisen from a coevolutionary process to restrict the
emergence of cancer.
The induction of apoptosis by growth-deregulating lesions
such as Myc, E2F, and loss of Rb has far reaching implications.
Perhaps the most fundamental is the idea that the combination
of deregulated proliferation and suppressed apoptosis consti-
tutes the minimal platform upon which all neoplasms reside.
How cells die, or not
A handbook of cell survivalPart 1
Since signals that drive entry into the cell cycle also prime the
apoptotic machinery, the ensuing fate of the cell is largely deter-
mined by the availability of local survival signals which, if pre-
sent, gate the apoptotic response. Thus, to understand cancer
we must first understand cell survival.
Survival signals take many forms, often peculiar to particu-
lar cell types. Perhaps the best described are the polypeptide
factors such as PDGF, NGF, chemokines, interleukins, and
IGFs that act through cognate receptor tyrosine kinases (see
later). In addition, the rapid death of many cell types upon matrix
detachment (anoikis) indicates that they derive necessary sur-
vival signals through their direct contact with neighbors or extra-
cellular matrix, typically mediated by integrins and cell adhesion
molecules (Frisch and Screaton, 2001). Other known survival
signals for specific cell types include steroids, lysophospho-
lipids, glucose in pancreatic β cells, and synaptic connections
for certain neuronal cells. Indeed, the only practical definition of
a survival signal is that its withdrawal triggers apoptosis.
However, even this pragmatic definition is not without complica-
tions, since the same factor can have very different effects in dif-
ferent cell types, or in the same cell under different conditions.
For example, EGF is a potent survival signal and mitogen for
many epithelial cells, but only a mitogen in fibroblasts. In the
case of BAF pro B cells, interleukin-2 (or interleukin-3) and
serum together serve to promote survival, whereas exposure to
interleukin in the absence of serum triggers rapid upregulation
of c-Myc and expeditious apoptosis (Shi et al., 1997).
The ability of survival factors to protect specifically from
oncogene-induced apoptosis was first noted with c-Myc, where
Myc-induced apoptosis was profoundly inhibited in fibroblasts
by serum (Evan et al., 1992) or IGF-1 (Harrington et al., 1994a)
and in myeloid cells by IL-3 (Askew et al., 1991).Whether or not
cell death occurs, Myc is an equally potent inducer of cell prolif-
eration. However, in the presence of survival factors, cells sur-
vive and accumulate. In other cases, activated oncogenes may
innately provide both proliferation/apoptosis signals and sur-
vival signals, albeit through different effector pathways. Thus,
oncogenic Bcr-Abl, the principal lesion underlying chronic myel-
ogenous leukemia, induces expression of c-Myc (Sawyers et
al., 1992) but also produces potent anti-apoptotic signals
(Amarante-Mendes et al., 1997). Similarly, oncogenic Ras can
elicit both apoptosis and survival via its differing downstream
effector pathways (Kauffmann-Zeh et al., 1997).
Surviving the lethal insult of oncogene activation is a pre-
requisite to establish a platform on which the cancer process
can build, and therefore the way cell death is controlled is cen-
tral to an understanding of cancer itself.
Death of a proliferating cellNo great loss
Cell type and tissue of origin have a significant influence on
the very earliest stages of tumorigenesis simply because differ-
ent tissues employ differing strategies to limit runaway cell
expansion. Perhaps the most obvious is for a tissue to be post-
mitotic and its component cells thereby inured to neoplastic
mutation. However, this is not a universally appropriate strategy
in vertebrates, because many tissues are required to undergo
continuous or episodic renewal. More generally, tissues limit
exposure of proliferating cells to mutation by restricting self-
renewal to a limited cadre of stem cells. Superficial epithelia,
such as gut and skin, further curb accumulation of proliferating
Figure 2. Death by receptor
Trimeric death ligands engage their death receptors (probably also trimer-
ic) to trigger intracellular events leading to apoptosis. The death domains
(DD) of the receptor bind to a DD on the adaptor protein FADD, exposing a
death effector domain (DED). This binds to a DED in the prodomain of pro-
caspase 8. Bringing two procaspase 8 molecules together results in their
auto-activation to a mature initiator caspase, which cleaves and activates
executioner caspases. The pathway shown applies to some death recep-
tors (e.g., Fas, Trail-R), while others are more complex (e.g., TNF-R1).
Oncogenic signals that promote apoptosis can increase expression of
death ligands and/or death receptors, and increase sensitivity to the
apoptotic signaling events, downstream of those shown here.
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cells by depositing all progeny on a one-way conveyer belt to
the surface, where the cells are then promptly shed. It is
axiomatic that derailment of this conveyer is a prerequisite for
neoplasia in such a tissue. For most other tissues, apoptosis is
the preferred sink for excess cells that must be overcome for
tumorigenesis to gain a foothold.
The executioner’s scissors
Although any form of regulated cell death is potentially relevant
to our thesis, we will focus on that morphologically defined type
of active cell death termed “apoptosis” (Wyllie et al., 1980). The
principal molecular engines that execute apoptosis, the killing of
the cell and its packaging for phagocytic removal, are the cas-
pase proteases that precipitate the apoptotic process by cleav-
ing critical cellular substrates. However, caspase activation is
not necessarily consonant with cell death: on the one hand, it is
apparent that cells can survive limited caspase activation (Alam
et al., 1999) and conversely, that inhibiting caspases will often
block the morphological manifestations of apoptosis, but cell
death proceeds nevertheless. The existence of such caspase-
independent cell death is significant since it intimates that cell
death is a highly redundant process that can be thwarted in can-
cer cells only with great difficulty.
Caspases are highly specific cysteine proteases, most
cleaving tetra- or pentapeptide recognition sequences at a P1
aspartate residue. They are synthesized as zymogens and
activated by cleavage at aspartates that are themselves in
caspase sites to generate the large and small subunits of the
mature enzyme. The “initiator” caspases, such as caspases 8
and 9, are typically low abundance zymogens whose extensive
prodomains mediate their oligomerization and autoactivation in
response to specific upstream signals. The best documented
pathways of initiator caspase activation are the assembly of the
Death Induced Signaling Complex (DISC) induced by ligation of
the TNFR1, CD95/Fas and Trail death receptors (Figure 2), and
the formation of the cytosolic apoptosome (Figure 3). The DISC
forms when death receptor ligation triggers association of the
intracellular adaptor protein FADD with the cytoplasmic tail of
the receptor. FADD then recruits procaspase 8 into the DISC,
whereupon the procaspase undergoes spontaneous autoacti-
vation (Figure 2). The apoptosome forms when signals trigger
release of holocytochrome c from mitochondria, which then trig-
gers assembly of the Apaf-1/caspase 9 holoenzyme (Figures 3
and 4).
Downstream of these initiators are the effector caspases,
such as caspases 3 and 7, abundant proteases that cleave cel-
lular substrates and precipitate apoptotic death. Some of the
key substrates of these “executioner’s scissors” are known. For
example, caspase 3 cleavage and inactivation of the nuclease
inhibitor iCAD liberates the CAD nuclease to cleave the DNA
(Enari et al., 1998), aiding in the subsequent rapid degradation
of the cell following its uptake by phagocytes. Caspases also
promote the efficient phagocytosis and disposal of apoptotic
cells by triggering membrane blebbing through cleavage and
activation of several enzymes, including gelsolin, p21-activated
kinase, and ROCK-1 (Coleman et al., 2001; Kothakota et al.,
Figure 3. Death by MOMP
Pro-apoptotic signals lead to mitochondrial outer membrane permeabi-
lization (MOMP), releasing proteins that reside in the mitochondrial inter-
membrane space and disrupting mitochondrial function. Cytochrome c
promotes the formation of an apoptosome that activates procaspase 9,
which in turn activates executioner caspases to orchestrate apoptosis.
Other released proteins, loss of mitochondrial function, and production of
reactive oxygen species all promote death that can proceed in a cas-
pase-independent manner. Oncogenic signals the promote apoptosis
stimulate events upstream of MOMP and can elevate the levels of the
components of the apoptosome. The mitochondrion shown is a tomo-
graph of an organelle that has undergone MOMP in an in vitro system
(courtesy of Dr. Don Newmeyer).
Figure 4. The apoptosome: A wheel of death
Monomeric Apaf-1 probably persists in its inactive form by interaction of its
N-terminal region with the WD domains in the C-terminal region. When
cytochrome c binds to the WD region, the protein unfolds, exposing an
oligomerization domain. Upon stabilization by dATP or ATP, a seven-spoked
oligomer forms. Caspase recruitment domains (CARDs) in the hub of the
oligomer bind to the CARDs of procaspase 9 molecules to activate them.
The activated caspase 9 cleaves and activates executioner caspases to
orchestrate apoptosis. (Modified from Acehan et al., 2002).
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1997; Rudel and Bokoch, 1997; Sebbagh et al., 2001), and
through their promotion of “eat me” signals, such as the exter-
nalization of phosphatidylserine (Fadok et al., 2001).
How activated oncogenes promote apoptosis
Oncogenes and death receptors
Multiple mechanisms underlie the induction of apoptosis by
oncogenes. One is via pathways mediated by the death recep-
tors such as TNFR1, Trail, or CD95/Fas. In T lymphocytes,
activation and cell cycle entry engages an apoptotic process
mediated by expression of Fas-ligand and engagement of Fas
sigaling (Sharma et al., 2000). This engagement is dependent
on c-Myc (Shi et al., 1992), which induces expression of Fas-lig-
and expression (Kasibhatla et al., 2000). Induction of apoptosis
in rodent fibroblasts by Myc is also dependent upon Fas-Fas-lig-
and interactions (Hueber et al., 1997), although in this case, the
relationship has more to do with Myc expression sensitizing
cells to a preexisting Fas signal. Likewise, expression of the
adenovirus oncoprotein E1A, which also drives both cell cycle
entry and apoptosis, sensitizes cells to apoptosis induced by
the death ligands TNF, Fas-ligand, and TRAIL (Routes et al.,
2000). E1A-induced apoptosis is p53-dependent (Debbas and
White, 1993) and may involve p53-induced upregulation of the
TRAIL death receptor, DR5 (Sheikh et al., 1998). However, E1A
and p53 seem to induce apoptosis predominantly through the
mitochondrial-apoptosome pathway, as discussed below.
Engagement of death receptor pathways by Myc and E1A
appears to occur via downstream effector pathways that are dis-
tinct and independent from cell cycle progression. This again
underscores the fundamental point that the pro-apoptotic
actions of activated oncogenes are not merely the conse-
quences of defective proliferation but discrete mechanisms that
have evolved in animals with long life spans to ameliorate the
oncogenic risk of cell proliferation.
Mitochondria and the activation of caspase-9
Whereas caspase 8 is activated in the death receptor DISC, the
initiator caspase 9 is activated in the cytosol through binding to
its adaptor, Apaf-1 (apoptotic protease activating factor-1) in a
homotypic interaction mediated by their shared CARD domains
(Figure 4). This happens when Apaf-1 is activated to oligomer-
ize by holocytochrome c (Zou et al., 1997) and, in turn, Apaf-1
activates caspase 9 without any requirement for caspase 9
cleavage (Stennicke et al., 1999). The active cytochrome
c/Apaf-1/caspase 9 complex has been nicknamed the “apopto-
some.”
Activated oncogenes are known to facilitate apoptosome
assembly and activation in various ways. For example, aden-
ovirus E1A induces upregulation of both Apaf-1 and procas-
pase-9 (Fearnhead et al., 1998). Levels of Apaf-1 in cells may
be limiting, so elevation of Apaf-1 would presumably increase
sensitivity of apoptosome activation to cytochrome c release.
Likewise, E2F1 upregulates expression of Apaf-1 (Moroni et al.,
2001). It remains to be seen whether other pro-apoptotic onco-
genes such as Myc and Ras similarly upregulate Apaf-1 and/or
procaspase-9. However, the most significant and crucial contri-
bution made by activated oncoproteins in the activation of the
apoptosome seems to be at the point of holocytochrome c
release from mitiochondria.
In any individual cell, the onset of cytochrome c loss from
mitochondria is sudden, occurs after a variable time since the
apoptotic insult, and involves the rapid and complete release of
cytochrome c from all mitochondria (Goldstein et al., 2000). In
addition, a variety of other proteins are also released from the
mitochondrial intermembrane space at the same time, and
many of these have their own discrete roles in promoting apop-
tosis (see below). Such dramatic discharge of mitochondrial
contents is a result of mitochondrial outer membrane permeabi-
lization (MOMP), although significant controversy surrounds the
mechanism responsible for MOMP in apoptosis (Martinou and
Green, 2001) (Figure 5). Model 1 favors a major role for mito-
chondrial function in sensing and precipitating MOMP. In con-
trast, Model 2 views the mitochondrion as a passive lockbox full
of deadly apoptogenic factors that are unleashed when pro-
apoptotic effectors compromise the integrity of the outer mito-
chondrial membrane.
MOMP in caspase-dependent and independent cell death
Although cytochrome c is necessary for activation of the Apaf-
1/caspase 9 apoptosome, downstream activation of the execu-
tioner caspases can nonetheless be forestalled by the IAPs
(inhibitor of apoptosis proteins), which act as endogenous cas-
pase inhibitors. X-linked IAP (XIAP), and probably other IAPs,
binds to active caspase-9 and inhibits its activity. Furthermore,
XIAP (and other IAPs) function as E3-ubiquitin ligases that tar-
get active caspases for rapid degradation (Suzuki et al., 2001b).
Figure 5. Models of MOMP
Pro-apoptotic BH3-only members of the Bcl-2 family are activated by vari-
ous signaling events, and these trigger the activation of BH-123 proteins
(which include Bax, Bak, and Bok). These oligomerize and insert into the
mitochondrial outer membrane. The models to account for MOMP during
apoptosis have been reviewed elsewhere (Martinou and Green, 2001).
Superficially, in Model 1, this event and various other signals promote
MOMP by altering the behavior of the mitochondria by (A) a permeability
transition, in which an opening of the adenine nucleotide transporter in the
inner membrane causes matrix swelling, leading to outer membrane dis-
ruption (Zamzami and Kroemer, 2001), or (B) VDAC closure, in which meta-
bolic signals in the cell trigger a closure of the voltage-dependent anion
channel in the outer membrane, resulting in inner membrane perturbations
that cause matrix swelling and outer membrane disruption (Vander Heiden
and Thompson, 1999). In contrast, in Model 2, the oligomerized BH-123 pro-
tein causes the permeabilization of the outer membrane directly, without
contributions from mitochondrial processes. This is the pore-forming model
in which MOMP is mediated by a pore or other permeability change in the
outer membrane, permitting protein release without involving the inner
membrane (Waterhouse et al., 2001; Wei et al., 2001). The mitochondria
shown are cartoons modified from the tomograph in Figure 4.
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XIAP, and probably other IAPs, are in turn regulated by at least
two polypeptides also released from mitochondria upon MOMP,
Smac/DIABLO (Du et al., 2000; Verhagen et al., 2000), and
Htra2/Omi (Hegde et al., 2002; Suzuki et al., 2001a; Verhagen
et al., 2002). These bind to XIAP via an AVP(I/S) sequence at
their N termini and thereby incapacitate IAP inhibition of cas-
pases.
There is also evidence that other proteins within the mito-
chondrial intermembrane space can promote cell death in cas-
pase-independent ways. One example is Htra2/Omi, which in
addition to its ability to block IAPs, appears to promote caspase-
independent cell death via its intrinsic serine protease activity
(Hegde et al., 2002; Suzuki et al., 2001a). Another is AIF (apop-
tosis inducing factor), which upon its release translocates to the
nucleus where it appears to induce chromatin condensation
(Susin et al., 1999). Finally, EndoG nuclease is thought to
directly mediate nuclear DNA fragmentation upon its release
from the mitochondrial intermembrane space (Li et al., 2001).
Another major consequence of MOMP is degeneration of
the electron transport chain that is required for most of the
organelle’s functions. While this loss occurs rapidly upon cas-
pase activation, it can also be caspase independent.The conse-
quent disruption of ATP generation, which in the absence of
caspase activation typically declines within hours or days of
MOMP (depending on the cell and the nature of the apoptosis-
inducing stimulus) (Goldstein et al., 2000; Waterhouse et al.,
2001), ensures the ultimate demise of the cell, although the
mode of cell death may more closely resemble necrosis than
classical apoptosis. In addition, the breakdown of electron
transport promotes the generation of reactive oxygen species
which may also hasten cell death.
The relative importance of loss of mitochondrial function,
caspase activation, and the caspase-independent actions of
other death-promoting proteins in the death of any cell in any
instance remains unresolved. However, such diversity and
redundancy in cell suicide mechanisms implies an equivalent
diversity in the mechanisms that tumor cells are likely to employ
in their need to thwart apoptosis. Consequently, identification of
the peculiar anti-apoptotic strategy adopted by each tumor type
would shed light on the particular pro-apoptotic pathways that
have shaped the development of that specific neoplasm and
indicate how best to reinstate the defective suicide program.
MOMP and the commitment to cell death
For a survival signal to participate in the process of oncogene-
sis, it must act before a cell is irrevocably committed to die.
Where, in the pathways we have been discussing, does such
commitment occur? In those cells in which death receptor sig-
naling is completely dependent on the activation of caspase 8,
inhibition of this caspase can confer protection from the lethal
consequences of death receptor signaling. In most cases of
apoptosis, however, the signals leading to MOMP precede cas-
pase activation and occur in a caspase-independent fashion.
When this happens, can inhibition or loss of caspase activation
result in cell survival?
We have surprisingly little information on the viability of cells
post-MOMP, although factor-deprived neurons have been
shown to survive for several days after the release of
cytochrome c provided caspase activation is blocked. Upon
return of growth factors, the neurons regenerate functional mito-
chondria and exhibit long-term survival (Deshmukh et al., 2000;
Martinou et al., 1999). However, in the case of transformed cells
transiently exposed to a variety of pro-apoptotic insults (Myc or
E1A oncoproteins, etoposide, UV, staurosporine, actinomycin
D), the presence of caspase inhibitors suppresses classical
apoptosis but the cells nonetheless exhibit total loss of clono-
genicity (Amarante-Mendes et al., 1998; McCarthy et al., 1997).
Thus cells may survive but retain zero neoplastic potential.
Mice lacking elements of the postmitochondrial apopto-
some (e.g., Apaf-1−/− mice, caspase-9−/− mice, and to a lesser
extent, caspase 3−/− mice) show profound developmental
defects attributable to inhibition of apoptosis, including craniofa-
cial abnormalities and a grossly enlarged cortex which often
extrudes through the skull (Mak and Yeh, 1999). While these
developmental effects may support the idea that events down-
stream of MOMP can act to preserve proliferative capacity of a
cell, another possibility exists. Cell death following MOMP pro-
ceeds more slowly in the absence than in the presence of cas-
pase activity, and from the period following MOMP until they
expire it is possible that cells preserve the ability to produce sur-
vival factors for other cells. Those cells that may depend on
these will therefore receive more survival factors when their
providers die via caspase-independent versus caspase-depen-
dent mechanisms. As a result, more cells accumulate when
caspase activation does not occur. We do not know whether or
not the cells that amass in these mutant mice have ever under-
gone (and recovered from) MOMP, or if such alternate process-
es account for the effect.
From the perspective of cancer, then, the most important
question may be this: can inhibition or loss of the apoptotic path-
ways downstream of MOMP contribute to oncogenesis? Recent
reports suggest that the answer may be yes, although not with-
out important reservations. Mouse embryonic fibroblasts lack-
ing Apaf-1 or caspase-9 are reported to be more readily trans-
formed by oncogenes than their wild-type counterparts
(Soengas et al., 1999), suggesting that inhibition of apoptotic
machinery post-MOMP can indeed contribute to oncogenesis.
However, no demonstration of recovery from MOMP (e.g., cells
that released cytochrome c but nevertheless recovered and
proliferated) was attempted, and no rigorous examination of
p53 status in these cells was performed (any loss of p53 func-
tion in these cultured cells, which is common, would greatly
enhance transformation on its own). Therefore, while provoca-
tive, these results are not definitive. However, some support for
a role of downstream apoptotic events in oncogenesis comes
from studies of human melanoma lines, where the majority of
cells show reduced or absent Apaf-1 expression (Soengas et
al., 2001). On the other hand, a similar loss of Apaf-1 activity in
human ovarian carcinoma lines showed no correlation with sus-
ceptibility to apoptosis (Wolf et al., 2001).
We are left with only the possibility that regulation of apop-
tosis downstream of MOMP can influence cell survival and
therefore oncogenesis. For example, the heat shock protein-70
(HSP-70) molecular chaperone is induced by diverse stresses
and has been shown to enhance transformation by oncogenes
(Beere and Green, 2001). Provocatively, HSP-70 can inhibit
activation of caspase-9 by Apaf-1.
MOMP and the Bcl-2 family
While it remains uncertain that cells can survive MOMP, it is
nonetheless clear that MOMP is a major player in the determi-
nation of loss of cell viability. Recently, the Bcl-2 family proteins
have emerged as fundamental regulators of MOMP. The Bcl-2
family members come in three flavors: anti-apoptotic, pro-apop-
totic “BH-123” proteins, and the pro-apoptotic “BH3 only” pro-
teins. The known anti-apoptotic members include Bcl-2, Bcl-xL,
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Mcl-1, Bcl-w, and A1, some of which are frequently expressed
in primary human cancers. The pro-apoptotic BH-123 proteins
share three of the Bcl-2 homology (BH) domains with the anti-
apoptotic proteins and include Bax, Bak, and Bok. The pro-
apoptotic BH3-only proteins possess only the BH3 domain nec-
essary for their pro-apoptotic activity, and include Bid, Bim, Bik,
Bmf, Bad, Hrk, BNIP3, Noxa, and Puma. Bcl-2, Bcl-xL, Bax, and
Bid share similar 3D structures that have an intriguing resem-
blance to the pore-forming chains of some bacterial toxins.
From this has come the idea that they act as pores in the mito-
chondrial membrane. Indeed, Bcl-2, Bcl-xL, Bax, and Bid have
all been shown to have weak channel-forming activity for small
ions through lipid membranes, although whether this is how
they regulate apoptosis remains controversial (Martinou and
Green, 2001).
The anti-apoptotic proteins Bcl-2 and Bcl-xL block MOMP in
cells and in cell-free systems, while the pro-apoptotic BH-123
members Bax and Bak promote it. Furthermore, cells and iso-
lated mitochondria from mice lacking both Bax and Bak (but not
one or the other) exhibit dramatic resistance both to induction of
MOMP and to the activation of the mitochondrial pathway of
apoptosis (Lindsten et al., 2000), indicating that Bax and Bak
fulfill a redundant function intimately (and perhaps directly)
involved in MOMP.
In the absence of apoptotic signals, the pro-apoptotic Bax
protein exists as an inactive monomer that can be induced to
oligomerize and migrate to the mitochondria by various BH3-
only proteins (Eskes et al., 2000). Such oligomerization at the
mitochondrion correlates with induction of MOMP, hinting that
there is a direct connection between the two. One model is that
monomeric Bax protein is folded in such a way that its BH3
domain is hidden, but exposed upon binding of an activating
BH3-only protein. This activated Bax then interacts with a sec-
ond Bax monomer, displacing its BH3 domain and so on, creat-
ing a chain reaction of pro-apoptotic Bax activation and
oligomerization. Oligomerized Bax then either generates a pore
or otherwise alters the integrity of the outer mitochondrial mem-
brane. In this scenario, the role of the anti-apoptotic Bcl-2 pro-
teins is to sequester and staunch the activated Bax and/or BH3-
only proteins and so prevent or curtail the lethal chain reaction
(Cheng et al., 2001). It is unclear if Bax or other BH-123 proteins
act on the mitochondrial outer membrane alone or in concert
with other proteins in the outer membrane, such as the voltage-
dependent anion channel (Shimizu et al., 2001).
The oncogenic consequences of inhibition of MOMP
through upregulation of the anti-apoptotic Bcl-2 proteins are
most strikingly illustrated in human follicular B cell lymphoma, in
which a reciprocal t(14;18) translocation deregulates Bcl-2
expression through fusion with the immunoglobulin heavy chain
enhancer. The initial result is an indolent tumor whose expan-
sion appears to depend on availability of normal B cell growth-
promoting signals. Subsequently, the lymphoma cells accumu-
late additional mutations (e.g., loss of p53 function and/or
expression of c-Myc) and a much more aggressive tumor
emerges. This process is thought to be recapitulated in trans-
genic animal systems, where enforced coexpression of Bcl-2
greatly accelerates Myc-induced B cell lymphomagenesis, pre-
sumably because Bcl-2 blocks c-Myc-induced apoptosis while
c-Myc overcomes the growth suppressive action of Bcl-2.
Much of the control of apoptosis is determined by the many
and diverse BH3-only proteins. However, it is not known if the
primary role of BH3-only proteins is to activate the BH-123
killers, inactivate the Bcl-2 protectors, both, or neither. The best
guess is that the BH3-only proteins each act as a terminal apop-
totic effector, coupling a specific pro-apoptotic signaling path-
way to the mitochondria. Consistent with this, the different BH3-
only proteins show diverse patterns of tissue expression and
transcriptional control. For example, Noxa (Oda et al., 2000)
and Puma (Nakano and Vousden, 2001; Yu et al., 2001) are
both induced by activated p53 and are presumed to be impor-
tant mediators of the apoptotic response to genotoxic damage.
In addition, however, much of the regulation of BH3-only pro-
teins is posttranscriptional. Thus, Bim (Puthalakath et al., 1999)
and Bmf (Puthalakath et al., 2001) are normally associated with
the cytoskeleton and are activated by release from this com-
partment, which may occur upon matrix detachment and under-
lie the mechanisms of anoikis (although they clearly play other
roles as well). Another BH3-only protein, Bid, is activated upon
cleavage by a number of different proteases, including caspase
8 (Budihardjo et al., 1999), the cytotoxic lymphocyte protease
Granzyme B (Pinkoski et al., 2001), and lysosomal proteases
(Stoka et al., 2001). A final example is the BH3-only protein
Bad, whose lethal action is blocked only so long as survival fac-
tor signaling via the serine/threonine kinase Akt/PKB (and other
kinases) keeps it phosphorylated and sequestered by the
cytosolic 14-3-3 proteins (Zha et al., 1996).
On the threshold of the abyss
The idea that the various BH3-only proteins serve as terminal
effectors of different signaling pathways to trigger MOMP offers
an explanation for the remarkable ability of cells to integrate so
many diverse pro- and anti-apoptotic influences. In effect, the
different BH3-only effectors integrate multiple signaling path-
ways at the mitochondria and distill them into a binary decision
that fires the apoptotic program should some threshold be
exceeded.
That apoptosis is triggered when some buffered threshold is
exceeded is suggested by the binary nature of the life-death
decision. It is also indicated by observations that cells can be
subjected to a variety of independently subcritical apoptotic
insults that when administered together trigger dramatic apop-
tosis. This additivity is directly relevant to oncogene-induced
apoptosis, which appears highly dependent upon the status of
other pro- and anti-apoptotic signaling such as cell type, sur-
vival factor availability, death receptor signaling, and DNA dam-
age (Evan et al., 1992; Harrington et al., 1994a; Hueber et al.,
1997; Juin et al., 1999). It is the net summation of the action on
MOMP of the oncoprotein, together with other existing pro- and
anti-apoptotic influences, that determines whether the firing
threshold is exceeded and the cell will die. One confusing con-
sequence of this is that it can often appear that there is one par-
ticular pathway or BH3-only protein that is pivotal in mediating
the cell death by a particular oncogene. In reality, however, that
particular pathway may merely be the final straw that breaks the
apoptotic camel’s back, as with Florida in the 2000 US presi-
dential election, where there was nothing special about that
state’s vote save that it was the last to be added to the tally.
Such considerations probably explain why oncogene-induced
apoptosis has been differently attributed to so many disparate
critical factors.
The handbook of cell survivalPart 2
While oncogenes and other pro-apoptotic signals combine to
erode the threshold for apoptotic firing, their effects are antago-
nized by a variety of anti-apoptotic mechanisms. As already
noted, pivotal determinants of cell survival in vivo are survival
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signals, without which all somatic cells undergo spontaneous
suicide (Raff, 1992). Some of the pathways by which survival
factors modulate apoptosis are now known, and many are
exploited by cancer cells. Perhaps the best-characterized sur-
vival signaling pathway is mediated by PI3-kinase, the intracel-
lular enzyme responsible for the generation of phosphoinositide
(3,4,5)P3. The resulting PIP3 binds the plecstrin homology
domain present in several kinases that foster cell survival and
thereby activates them. In this way, the AKT/PKB serine/threo-
nine kinase is activated in response to a variety of upstream sig-
nals, including ligation of cytokine receptors or integrins, as well
as by oncogenic activation of Ras (Stambolic et al., 1999).Once
activated, AKT promotes survival by several distinct mecha-
nisms. One is through phosphorylation of the BH3-only protein
Bad which, as outlined above, promotes its sequestration and
inactivation. Activated AKT also induces transcription of anti-
apoptotic Bcl-2 family members such as Bcl-xL (Sabbatini and
McCormick, 1999) and inhibits the Forkhead transcription factor
FKHRL1 (Brunet et al., 1999), which has a number of pro-apop-
totic transcriptional targets. AKT has also been shown to pro-
mote translocation of the p53 antagonist Mdm2 from the cyto-
plasm to the nucleus (Mayo and Donner, 2001). In addition, AKT
promotes expression of the glucose transporter Glut-1 (Barthel
et al., 1999) and activates the glycolytic enzyme hexokinase by
direct phosphorylation (Gottlob et al., 2001). Interestingly, AKT-
mediated survival is dependent on glucose, whereas survival
mediated by Bcl-xL is not (Gottlob et al., 2001; Plas et al., 2001),
raising the possibility that survival factors directly impact on
MOMP by sustaining mitochondrial metabolism.
Many tumors bypass the requirement for survival factor sig-
naling by engaging the AKT pathway in various ways. In many
instances, AKT is triggered by the relentless action of upstream
signaling molecules such as Ras or receptor tyrosine kinases
(Testa and Bellacosa, 2001). However, AKT is also overex-
pressed in some tumors, while activating mutations of the p85
subunit of PI3K are found in others. Finally, a significant number
of cancer cells have lost functional PTEN, the phosphatase that
dephosphorylates PIP3 to shut down AKT (Cantley and Neel,
1999), and therefore AKT remains active in these cells.
However, not all aspects of cell survival are determined by
the PI3-kinase-AKT signaling pathway. For example, the anti-
apoptotic effect of Bcr-Abl can be PI3-kinase-independent
(Amarante-Mendes et al., 1997). As already noted, at least part
of the attachment survival signal of epithelial cells may be medi-
ated by the sequestration of the BH3-only proteins Bim and Bmf
within the cytoskeleton (Puthalakath et al., 1999, 2001).
Another important determinant of cell survival is the
p65RelA-p50 transcription factor, NF-κB. NF-κB promotes cell
survival by antagonizing the apoptotic pathway triggered by
death receptors, at least in part through induction of expression
of IAP proteins. In addition, NF-κB can induce the expression of
anti-apoptotic members of the Bcl-2 family and repress expres-
sion of the BH-123 protein, Bax. Like most potentially oncogenic
signaling molecules, however, NF-κB also has a paradoxical
ability to promote cell death in some instances (Kuhnel et al.,
2000; Ryan et al., 2000).
Apoptosis and cancerLooking for the Achilles’ heel
The multiple ways that oncogenes prime the apoptotic program,
together with the critical combinatorial role played by other pro-
and anti-apoptotic influences in the life/death threshold deci-
sion, offers a huge repertoire of mechanisms that tumor cells
could exploit in their thirst for survival. Paradoxically, however,
oncogenic priming suggests that when tumors first arise, they
are actually more prone to induction of apoptosis than their nor-
mal counterparts.This innate sensitivity is probably the basis by
which most existing anti-cancer therapies act. For example, the
traditional rationale for using DNA-damaging agents as cancer
therapeutics was the plausible idea that cancer cells cycle more
rapidly than normal cells and are therefore more susceptible to
anti-proliferative agents. However, it is now evident that this sus-
ceptibility has more to do with the potent pro-apoptotic signals
induced by DNA damage: signals to which cancer cells are
innately more susceptible by virtue of oncogenic priming of their
apoptotic program (Evan and Littlewood, 1998). Unfortunately,
any initial susceptibility of the genetically plastic tumor cell
becomes rapidly eroded under the selective duress of therapy.
The unhappy result is the all too common reemergence of a
resistant and deadly tumor. Arguably the greatest problem with
the conventional therapeutic approach is that it fails to correct
the tumor’s specific anti-apoptotic lesion(s) and instead
employs a cruder strategy of simply loading up the pro-apoptot-
ic side of the equation in the hope of exceeding the apoptotic
threshold in the tumor cells before it happens in too many nor-
mal ones. If susceptibility to apoptosis really is the Achilles’ heel
of the cancer cell, we need to know far more about the footwear
Figure 6. The cancer platform
Cells that have deconstrained proliferation with reduced cell death have
attained a cancer platform that can spontaneously yield the features
associated with morbidity and mortality. The cancer platform itself results in
expansion of the tissue (1). The growing tumor will display features associat-
ed with the expansion of the normal tissue, and these features will vary with
the cell type (2). These can include recruitment of a blood supply, infiltra-
tion into neighboring tissues, and evasion of immune responses, among
others. Further, the precise alterations responsible for establishing the can-
cer platform can have additional effects that manifest in the growing
tumor (3). As the expanding tissue alters its environment (or moves into
other environments), selection of heritable variants results in the emer-
gence of new features that may be specific to the individual cancer (4).
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that protects it.
One glimpse of the Achilles’ heel has been provided by a
survey of 60 cancer cell lines treated with a large number of
chemotherapeutic agents, in which a number of possible anti- or
pro-apoptotic genes were examined (Amundson et al., 2000).
Of these, only Bcl-xL level correlated with resistance to cell
death induced by various therapeutics. Some take this correla-
tion as an indication that Bcl-xL is the major target to be over-
come for effective therapy.However, it remains unknown to what
extent such upregulation of Bcl-xL is an adaptation to breast
cancer in vivo as opposed to established growth in vitro.
Unfortunately, Bcl-xL is not expressed in all tumors, and so can-
not be the lesion responsible for survival of many other tumor
cell types. Nonetheless, such data do indicate that tumor evolu-
tion favors adoption of specific and restricted pathways of apop-
tosis suppression. We have little idea of the repertoire of anti-
apoptotic mechanisms in human cancer, which is unfortunate,
as it may be only by targeting the specific anti-apoptotic lesion
in any tumor cell that we will be able to ensure its rapid and spe-
cific demise.
When good cells go bad
Building on the cancer platform
Although few would argue with the idea that tumors minimally
require deconstrained cell proliferation together with sufficient
survival to ensure cell expansion, it is widely assumed that
tumor progression involves the stochastic acquisition of addi-
tional traits such as the capacity for invasion, metastasis, and
angiogenesis.We venture to suggest, however, that many, per-
haps most, of these traits emerge spontaneously once the plat-
form for cell expansion has been established (Figure 6). Some
may simply be the properties of proliferating cells. For example,
proliferating cells differ from their quiescent counterparts meta-
bolically, in their differentiation state, in degrees of cell adhesion
and migration, and in basic morphological features such as
nuclear:cytoplasmic ratio. Others may be the traits of expanding
tissues which, by necessity, elicit complex iterative responses in
their surroundings that manifest as angiogenesis, invasion, and
evasion of immune responses. Indeed, many of the signature
aspects of the “tumor-specific” phenotype—expansion, dyspla-
sia, anaplasia, angiogenesis, and invasion—are also seen in
those rare tissues that undergo expansion in the adult, such as
trophoblasts, mammary glands, and female reproductive
organs. Thus, normal and neoplastic tissues may differ not so
much in how they expand but in how that expansion is regulat-
ed: in the former expansion stops in response to appropriate
cues, while in the latter expansion continues unabated, driven
by neoplastic lesions that short-circuit the need for extracellular
signals.
In addition, suppression of apoptosis also has the cata-
strophic potential of promoting mutation and genome instability.
Of course, inhibition of apoptosis is not innately mutagenic, but
since apoptosis is a major avenue for disposal of mutated or
damaged cells, its suppression could permit the survival of cells
that would otherwise have been expeditiously deleted. In this
regard, not all anti-apoptotic lesions are likely to be equal. For
example, evasion of oncogene-induced apoptosis through
upregulation of Bcl-xL might be expected to confer significant
resistance to DNA damage-induced apoptosis. However, if the
p53 pathway remained intact, the affected cell could still mount
a protective response to the insult, perhaps by triggering growth
arrest or a MOMP that overwhelms Bcl-xL protection. In con-
trast, loss of p53 would dislocate the DNA damage response
from the apoptotic machinery while leaving the apoptotic
machinery intact. Such a cell would presumably survive and
accumulate DNA damage yet remain susceptible to p53-inde-
pendent triggers of apoptosis.
Any contribution that suppression of apoptosis might make
to genome plasticity could have profound consequences for
tumor progression. As prototumors evolve, they will confront,
and be shaped by, shifting selective pressures that vary in
extent, potency, and location. When such selection becomes
superimposed on significant genome plasticity, the result will be
the evolutionary smorgasbord of heterogeneity and adaptability
that makes treatment of advanced cancers seem so intractable.
By this stage in somatic evolution, even its description by the
single word “cancer” becomes questionable.
A matter of life and death
Notwithstanding this pessimistic assessment, our hypothesis
remains that even the most heterogeneous and diverse of can-
cers share a common and obligate mechanistic ancestry: all
teeter precariously on the same platform of deregulated prolifer-
ation and reduced cell death. We suspect that cutting the legs
from under this platform should topple the supported neoplastic
structure. 60 years ago, the doom and gloom surrounding the
bewildering diversity of pathologies inflicted by bacteria, multi-
ple species evolving at breathtaking rates, fell prey to the antibi-
otics that laid bare their common heritage. Now, we want antibi-
otics for cancer.
Given its mechanistic simplicity, we have only two options to
collapse the cancer platform. One is to attack the lesions that
drive tumor cell proliferation, which might lead not only to tumor
cell arrest but have additional therapeutic benefits if emergent
processes like dedifferentiation and angiogenesis are also con-
tingent upon deregulated cell proliferation (Evan and Vousden,
2001). Alternatively, we could reinstate the defective apoptosis,
whereupon the tumor cell should die from the apoptotic depre-
dations inflicted on it by its driving oncogenic lesions.
Unfortunately, while this second leg of the platform would
seem to offer the most auspicious targets, as already noted, we
are enormously handicapped by our comparative ignorance of
the diversity and nature of anti-apoptotic mechanisms in cancer.
Nonetheless, this may be the principal mechanism by which
antibodies to HER2/neu or the EGFR, both of which can provide
survival signals, are effective in therapy in vivo. Similarly, STI-
571 targeting of Bcr-Abl appears to trigger apoptosis in CML
(Gambacorti-Passerini et al., 1997), while antisense inhibition
of Bcl-2 has shown some therapeutic efficacy in lymphomas,
myelomas, and other hematologic malignancies (Flaherty et al.,
2001). Another focus of interest is the p53 pathway, whose rein-
statement might trigger the specific demise of cells with dam-
aged genomes or activated oncogenes. Some attempts have
been made to reactivate p53 function in tumor cells by gene
transfer, through agents that force mutant p53 back into its wild-
type configuration, and by inhibiting negative regulators of p53
such as MDM2 in those tumors that retain wild-type p53 (Woods
and Vousden, 2001). However, the ultimate clinical utility of such
strategies is presently unclear. Another intriguing idea is to con-
vert anti-apoptotic signals or proliferative signals needed by the
tumor cells into signals that trigger apoptosis. For example, relo-
cation of anti-apoptotic Bcr-Abl from cytosol to the nucleus
appears to cause this oncogenic survival signal to trigger cell
death (Vigneri and Wang, 2001). Similarly, inhibition of
cyclin/cyclin-dependent kinase 2 has been shown to induce
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selective apoptosis of transformed cells by commandeering the
innate pro-apoptotic potential of E2F (Chen et al., 1999).
Like antibiotics, all forms of cancer therapy risk selecting for
resistance, a problem compounded by the plasticity of the tumor
cell genome.The most effective strategy is likely to be combina-
torial—a coordinate attack on several targets specific to the
cancer. Indeed, in such a strategy, it may not even be necessary
for each component to be specific for cancer cells, so long as
the combination provides selective ablation. The evolution of
such sophisticated forms of combined therapy will undoubtedly
proceed by a process that employs both rational and empirical
approaches. However, a concerted attack on the lesions sup-
porting the common cancer platform may well provide generic
opportunities for effective and specific cancer treatment. By the
very nature of the cancer platform, a cancer cell would be most
sensitive to the restoration of those apoptotic pathways that is
has specifically suppressed. We must find out what those are,
and urge a cancer to its own demise.
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